Search

Author/Creator Fransecky, Lars

1. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Issue 12 (December 2018)

Authors:
Platzbecker, Uwe; Middeke, Jan Moritz; Sockel, Katja; Herbst, Regina; Wolf, Dominik; Baldus, Claudia D; Oelschlägel, Uta; Mütherig, Anke; Fransecky, Lars; Noppeney, Richard; Bug, Gesine; Götze, Katharina S; Krämer, Alwin; Bochtler, Tilmann; Stelljes, Matthias; Groth, Christoph; Schubert, Antje; M...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 12(2018)
Page Start:
1668
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search